Thiazolidinediones (TZDs), synthetic peroxisome proliferator-activated receptor (PPAR)-g ligands, have a central role in insulin sensitization and adipogenesis. It has been reported that TZDs exert protective effects in both diabetic and nondiabetic models of renal disease, although the exact mechanism is not well understood. In particular, only a few studies have reported the renoprotective effects of TZDs in nondiabetic models of tubulointerstitial fibrosis and inflammation. Therefore, we investigated the anti-fibrotic and anti-inflammatory effects of the TZD troglitazone in the mouse model of unilateral ureteral obstruction (UUO). C57BL/6J mice underwent UUO and were studied after 3 and 7 days. Animals were divided into three groups and received control vehicle, troglitazone (150 mg/kg per day) or troglitazone (300 mg/kg per day) by gavage. Kidneys were harvested for morphological, mRNA and protein analysis. Reversetranscriptase-PCR was used to assess the expression of transforming growth factor-b1 (TGF-b1) and the TGF-b1 type I receptor (TGFbR-I). Protein expression was assessed by western blotting (TGFbR-I) and immunostaining (TGFbR-I, a-smooth muscle actin (a-SMA), type I collagen (collagen I), F4/80, and proliferating cell nuclear antigen (PCNA)). The expression of a-SMA, collagen I, and F4/80 was decreased in mice treated with troglitazone compared with the control group. The numbers of PCNA-positive interstitial cells were decreased in mice treated with troglitazone. TGF-b1 mRNA and TGFbR-I mRNA and protein expression were decreased in the group treated with troglitazone compared with the control group. The beneficial effects of troglitazone treatment were also dose dependent. PPAR-g agonist significantly reduced TGF-b and attenuated renal interstitial fibrosis and inflammation in the model of UUO.
Progressive interstitial fibrosis represents a common final pathway of nearly all forms of chronic kidney disease. 1, 2 Following unilateral ureteral obstruction (UUO), renal tubular cell injury results from mechanical stretch, ischemia, hypoxia, or exposure to toxins such as oxygen free radicals. As a consequence, renal tubular epithelial cells may either undergo cell death by apoptosis or necrosis or undergo a phenotypic transformation and acquire mesenchymal characteristics. 3, 4 Peroxisome proliferator-activated receptor-g (PPAR-g) is a ligand-dependent transcription factor involved in the production of profibrotic and proinflammatory mediators. However, the role of PPAR-g in the inhibition of fibrosis in vivo has not been described.
PPAR-g belongs to the nuclear hormone receptor superfamily. 5 PPAR-g is selectivity expressed in medullary collecting ducts, glomeruli, and proximal tubular cells. [6] [7] [8] PPAR-g has a central role in regulating insulin sensitivity, adipocyte differentiation, cell growth, and inflammation. 9 Thiazolidionediones (TZDs) are synthetic PPAR-g agonists and are widely used as insulin-sensitizing agents in patients with type 2 diabetes. The beneficial effects of TZD treatment include blood pressure lowering, triglyceride reduction and high-density lipoprotein-cholesterol elevation as well as improving glycemic control. 10, 11 There are several clinical studies demonstrating a beneficial effect in patients with type 2 diabetes treated with TZDs, with patients exhibiting a reduction in albuminuria. 12, 13 In addition, a beneficial effect on urine albumin or protein excretion has been reported in animal models of insulin resistance, diabetes, and hypertension following treatment with TZDs 14, 15 with these benefits appearing to be independent of glycemic control. The renoprotective benefit of TZDs is further suggested by studies in nondiabetic models of renal injury. For example, activation of PPAR-g reduced glomerulosclerosis and apoptosis in various models including the 5/6 nephrectomy model, passive Heymann nephritis model, crescentic glomerulonephritis model, acute mesangial proliferative glomerulonephritis model, and renal ischemia-reperfusion injury model. [16] [17] [18] [19] [20] [21] In vitro studies have focused on the effect on mesangial cells, where PPAR-g activation exerts antiproliferative and antifibrotic effects 22, 23 via the modulation of transforming growth factor-b1 (TGF-b1)-mediated pathways. 24 TZDs also reduced the secretion of macrophage chemotactic protein-1 (MCP-1), a proinflammatory chemokine, in human HK-2 cells exposed to high concentrations of glucose. 7 However, there are few studies of the renoprotective effect of PPAR-g agonists in tubulointerstitial fibrosis and inflammation that develops in nondiabetic models, as tubulointerstitial disease is widely accepted as a final common pathway of chronic kidney disease that leads ultimately to end-stage renal failure.
The aim of this study was to evaluate the effect of troglitazone, a specific PPAR-g ligand, on tubulointerstitial fibrosis and inflammation in a model of UUO.
MATERIALS AND METHODS Experimental Model and Administration of Drug Treatment
Total of 56 female C57BL/6J mice weighing 20-25 g were obtained from Charles River Laboratories Japan (Yokohama, Japan). The animals were housed in the animal facility of Hiroshima University with free access to food and water. The Institutional Animal Care and Use Committee at Hiroshima University (Hiroshima, Japan) approved all the animal protocols and the experiments were performed in accordance with the National Institutes of Health Guidelines on the Use of Laboratory Animals. Troglitazone was kindly provided by Sankyo Daiichi Co. Ltd. (Tokyo, Japan). Troglitazone was prepared as a suspension in distilled water and administered by oral gavage (0.1 ml per mouse) at a dose of either 150 or 300 mg/kg per day twice per day. The control group was administered an equal volume of distilled water by gavage. In all groups, medication was started 7 days before surgery and continued until sacrifice. The last treatment was administered 3 h before sacrifice. Surgery was performed under general anesthesia induced by ketamine and xylazine as described previously. 25 The abdomen was opened using a midline incision and the left ureter was located and ligated twice with 4-0 nylon suture. Groups of eight mice were sacrificed on days 3 and 7 after UUO and renal tissue harvested. 26 
RNA Extraction and Quantitative Real-Time Reverse Transcriptase-PCR (qRT-PCR)
Total RNA was extracted from murine renal tissue using the RNeasy Mini Kit (Qiagen Inc., Valencia, CA, USA). Equal amounts (2 mg) of total RNA from each sample were converted to cDNA using moloney murine leukemia virus RT RnaseH with oligo dT20 primer in a 20 ml reaction volume. Quantitative real-time RT-PCR analysis was performed on a 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Gene-specific oligonucleotide primers and probes for TGF-b1 (assay ID: Mm03024053_m1) and its type I receptor (TGFbR-I) (assay ID: Mm03024015_m1) as well as the internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (assay ID: Mm99999915_g1) were obtained as TaqMan s Gene Expression Assays (Applied Biosystems). Amplification was performed with TaqMan s universal PCR master mix and universal cycling conditions (Applied Biosystems). Data analysis was performed using 7500 Fast System Sequence Detection Software version 1.4 (Applied Biosystems). The results of TGF-b1 and TGFbR-I were normalized to the expression level of GAPDH.
Antibodies
The following primary antibodies were used in the study: mouse monoclonal FITC-conjugated anti-a-smooth muscle actin (a-SMA) antibody (Sigma-Aldrich, St Louis, MO, USA), mouse monoclonal anti-a-tubulin antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), rat monoclonal anti-F4/80 antigen antibody (Serotec, Kidlinton, UK), rabbit polyclonal anti-collagen I (Abcam, Cambridge, UK), antiproliferating cell nuclear antigen (PCNA) (Santa Cruz Biotechnology Inc.), and anti-TGFbR-I, antibodies (Santa Cruz Biotechnology Inc.). Immunostaining with a-SMA, collagen I, F4/80, and TGFbR-I was used to identify myofibroblasts, collagen I, infiltrating macrophages, and TGFbR-I expression, respectively.
The following secondary polyclonal antibodies were used in the study: goat anti-mouse immunoglobulin (IgG) conjugated with HRP (Dako Cytomation, Glostrup, Denmark), biotinylated goat anti-rabbit immunoglobulin (IgG, H þ L) (Zymed, South San Francisco, CA, USA), and biotinylated rabbit anti-rat immunoglobulin (IgG, H þ L) (Zymed).
Western Blot Analysis
For detection of TGFbR-I, one-third of a kidney was homogenized on ice in 1 ml of lysis buffer (Cell Signaling Technology) and 1 mM phenylmethylsulfonyl fluoride. The homogenate was centrifuged at 15,000 g for 20 min to remove tissue debris and the supernatant was divided into aliquots and stored at À801C. The protein content of cell lysates was determined by a BCA protein assay (Pierce, Rockford, IL, USA). Western blotting was performed as described previously. 27, 28 The blots were incubated overnight at 41C with antiTGFbR-I antibody (1:1000 dilution) followed by washing and incubation with HRP-conjugated goat anti-rabbit IgG antibody (1:5000 dilution). Monoclonal anti-a tubulin antibody was used as the internal control for the analysis of TGFbR-I expression. The intensity of each band was estimated using National Institutes of Health Image software (NIH, Bethesda, MD, USA; version 1.6).
Immunohistochemistry
Immunohistochemical staining was performed on tissues fixed in 10% formalin and embedded in paraffin, as described previously. 21 The direct method was used for the detection of a-SMA and the ABC method was used for the detection of collagen I, F4/80, PCNA, and TGFbR-I. For a-SMA staining, sections were blocked in 5% bovine serum albumin (BSA) and 10% normal sheep serum in phosphatebuffered saline (PBS) for 60 min and then incubated overnight at 41C with the primary antibody diluted in 10% normal sheep and 5% normal mouse serum in PBS. After washing, endogenous peroxidase was blocked by incubation in 0.6% H 2 O 2 in methanol for 20 min. Sections were incubated sequentially with peroxidase-labeled antifluorescein (Vector Laboratories, Burlingame, CA, USA) for 45 min. Sections were developed with diaminobenzidine (Sigma) to give a brown color or with Vector SG (Vector Laboratories) to give a blue/gray color. Tissue sections requiring antigen retrieval treatment were placed in 0.01 M citrate buffer, pH 6.0, and heated for 15 min in a microwave oven. This treatment was used for detection of collagen I, F4/ 80, PCNA, and TGFbR-I. For collagen I, PCNA, and TGFbR-I (rabbit polyclonal antibodies) or F4/80 (rat monoclonal antibody) staining, sections were blocked in 5% BSA and 10% normal sheep or rabbit serum in PBS for 60 min, and then incubated overnight at 41C with the primary antibody in 10% normal sheep or rabbit serum and 5% normal mouse serum in PBS. After washing, endogenous peroxidase was blocked by incubation in 0.6% H 2 O 2 in methanol for 20 min. Sections were blocked in Avidin-Biotin blocking kit (Vector Laboratories) and then incubated sequentially with biotinylated goat anti-rabbit or rabbit anti-rat IgG for 45 min followed by incubation with the Vectastain Elite kit (Vector Laboratories). Sections were developed with diaminobenzidine to give a brown color.
Two color immunostaining was used to detect colocalization of a-SMA and PCNA. After staining for a-SMA followed by developing with Vector SG to give a blue/gray color, sections were placed in 0.01 M citrate buffer, pH 6.0, and heated for 15 min in a microwave oven. Sections were then blocked as above and incubated overnight at 41C with the polyclonal anti-PCNA antibody. Sections were then washed and blocked in Avidin-Biotin blocking kit and then incubated sequentially with biotinylated goat anti-rabbit IgG for 45 min, followed by incubation with the Vectastain Elite kit and then developed with diaminobenzidine to give a brown color. 29 
Quantification of Immunohistochemical Staining
The area of a-SMA, collagen I, and F4/80-positive staining was assessed in predetermined high power fields ( Â 200) of the cortex (eight fields) and the corticomedullary junction (eight fields) that were captured by a digital camera and the area stained determined using Lumina Vision 2.20 (Mitani Corporation, Osaka, Japan). Immunostaining for PCNA was quantified by examination of predetermined high power fields ( Â 400) of the cortex (10 fields) and the corticomedullary junction (10 fields). Scoring was performed using an eye-piece graticule and the number of PCNA-stained interstitial cells was expressed as cells per 0.5 mm 2 .
Measurement of Plasma Troglitazone and Blood Sugar Levels Blood samples were taken by cardiac puncture before harvesting tissue samples. The samples were centrifuged at 3000 g for 10 min at 41C and supernatants were aliquoted and stored at À801C. The troglitazone levels before UUO and at day 7 of the UUO model were measured by high-performance liquid chromatography at Daiichi Sankyo RD Associe Co. Ltd. (Tokyo, Japan). The lower limit of quantification is 0.2 mg/ml. In addition, the blood sugar levels of mice were measured using a Hitachi 7180 Automatic Analyzer (Hitachi High-Technologies Corporation, Tokyo, Japan) at SRL Inc.
(Tokyo, Japan).
Statistical Analysis
Results are expressed as means±s.e. for each group of eight mice. Statistical analysis was performed with ANOVA followed by Tukey's post hoc test unless otherwise stated. Data differences were deemed significant at Po0.05.
RESULTS

Troglitazone Suppressed the Interstitial Expression of a-SMA in UUO
The expression of a-SMA is the molecular hallmark of myofibroblasts, with the localization and quantification of myofibroblasts denoting the intensity of the fibrogenic response after UUO. a-SMA was expressed in the smooth muscle cells of renal arterioles but was rarely evident in the renal interstitium of normal kidneys ( Figure 1A-a) . Although ureteral obstruction resulted in a gradual though striking increase in the interstitial expression of a-SMA ( Figure 1A -b and e), troglitazone treatment resulted in a reduction in interstitial a-SMA expression ( Figure 1A -c, d, f and g). Quantification of immunostaining in renal tissue is shown in Figure 1B and indicates the marked increase in the a-SMApositive area in the experimental control group after UUO. Treatment with troglitazone significantly reduced interstitial expression of a-SMA in the treatment groups at both 3 and 7 days after UUO and these effects were dose dependent.
Troglitazone Suppressed the Interstitial Expression of Collagen I in UUO
The process of tubulointerstitial fibrosis involves the loss of renal tubules and the accumulation of extracellular matrix (ECM) proteins. Collagen I is one of these ECM proteins and in this study we showed collagen I was expressed in the renal arterioles, but was rarely evident in the renal interstitium of normal kidneys (Figure 2A Figure 2B , which 
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demonstrates the marked increase in the collagen I-positive area in the experimental control group after UUO. Treatment with troglitazone significantly reduced interstitial expression of collagen I in the treatment groups at both 3 and 7 days after UUO and these effects were dose dependent.
The Effect of Troglitazone on Renal Inflammation after UUO One of the early events in the development of tubulointerstitial fibrosis is the recruitment of inflammatory cells. Immunohistochemical staining for macrophages using Figure 3 Immunohistochemical staining for F4/80. (A) Representative photomicrographs of immunohistochemical staining for F4/80 (arrows) in the cortex of the control group before UUO (a), 3 days after UUO in the control group (b), 3 days after UUO in the group receiving troglitazone 150 mg/kg/day (c), 3 days after UUO in the group receiving troglitazone 300 mg/kg per day (d), 7 days after UUO in the control group (e), 7 days after UUO of the group receiving troglitazone 150 mg/kg per day (f), and 7 days after UUO in the group receiving troglitazone 300 mg/kg per day (g). (B) Graphical depiction of the F4/80-positive area of the cortex and the corticomedullary junction before and after UUO in the control group (white bars), the group receiving troglitazone 150 mg/kg per day (slash bars) and the group receiving troglitazone 300 mg/kg per day (black bars). Values are expressed as the mean±s.e. of seven groups of animals (8 mice per group). Magnification: Â 200. **Po0.01 by ANOVA with Tukey's post hoc test. Figure 4B and indicates a marked increase in the number of PCNA-positive interstitial cells in the experimental control group after UUO. Treatment with troglitazone significantly inhibited the proliferation of interstitial cells in the treatment groups at 3 and 7 days after UUO with the antiproliferative effects of troglitazone treatment being dose dependent. We also performed double staining of a-SMA and PCNA in control mice at 7 days after UUO in order to determine the proliferation of myofibroblasts ( Figure 4C ) and this demonstrated the presence of proliferating myofibroblasts after UUO. 
Troglitazone Inhibits the Expression of TGF-b1 and the TGF-b1 Type I Receptor We evaluated the effect of troglitazone on TGF-b1 mRNA, TGFbR-I mRNA, and TGFbR-I protein expression using realtime RT-PCR, western blotting, and immunostaining. The expression of TGF-b1 mRNA in the experimental control group gradually increased after UUO. In contrast, troglitazone treatment significantly inhibited TGF-b1 mRNA expression in the treatment groups at 3 and 7 days after UUO. The effects of troglitazone treatment on the expression of TGF-b1 mRNA were dose dependent (Figure 5a ). Expression of TGFbR-I mRNA in the experimental control group increased gradually after UUO. Troglitazone treatment significantly inhibited the upregulation of TGFbR-I mRNA Figure 7 Representative micrographs showed the expression and localization of TGF bR-I. Immunohistochemical staining for TGF bR-I (arrows) in the cortex before UUO in the control group (a), 7 days after UUO in the control group (b), 7 days after UUO in the group receiving troglitazone 150 mg/kg per day (c), and 7 days after UUO in the group receiving troglitazone 300 mg/kg per day (d). Magnification: Â 200. The lower limit of quantification (LLOQ) is 0.2 mg/ml.
expression in the treatment groups at both 3 and 7 days after UUO in a dose dependent manner (Figure 5b ). Western blotting analysis identified TGFbR-I and a tubulin in lysates of kidney tissue. Quantification of TGFbR-I protein expression by densitometric analysis demonstrated increased expression in the control group after UUO, with troglitazone treatment resulting in the significant inhibition of TGFbR-I protein expression in the treatment groups at 3 and 7 days after UUO. The effects of troglitazone treatment on the protein expression of TGFbR-I were also dose dependent ( Figure 6 ). Similar results were obtained when TGFbR-I expression by immunohistochemistry was analyzed ( Figure  7 ). Of note, TGFbR-I expression was localized in the tubular epithelial cells.
Plasma Levels of Troglitazone and Blood Sugar
The mean plasma levels of troglitazone in the control group before UUO and at 7 days after UUO were at the lower limit of quantification, whereas the levels in the treatment groups receiving troglitazone at a dose of 150 or 300 mg/kg per day were 0.388 ± 0.07 and 0.562 ± 0.05 mg/ml, respectively. The mean blood sugar level in the control group before UUO and at 7 days after UUO was 173.38±10.32 and 180.50±6.97 mg/dl, respectively. The mean blood sugar level in the treatment groups receiving troglitazone at a dose of 150 or 300 mg/kg per day was 190.88 ± 11.13 and 169.75 ± 5.49 mg/dl, respectively. There was no significant difference in the plasma blood sugar levels between the control group and the treatment groups (Table 1) .
DISCUSSION
We demonstrated that expression of a-SMA, collagen I, and F4/80 was decreased in the group treated with troglitazone compared with the control group. In addition, the number of PCNA-positive interstitial cells was decreased in mice treated with troglitazone. We also showed that troglitazone inhibited the expression of TGF-b1 and TGFbR-I in mouse kidneys following UUO. These results indicate that troglitazone can effectively reduce interstitial fibrosis and inflammation in the model of UUO. The plasma troglitazone concentration is reported as a peak level measured after oral and intravenous administration in mice 30, 31 and the dosage used in this study is not excessive in view of the short-term administration of 14 days. However, the troglitazone dosages we used in this study were greater than those used in humans. We chose these dosages as a pilot study had shown they resulted in normal blood glucose levels in the mice, whereas other studies had administrated troglitazone at dosages greater than 500 mg/kg per day. 32, 33 The expression of a-SMA is considered specific for myofibroblasts that may be derived from epithelial mesenchymal transdifferentiation (EMT). Elongated myofibroblasts expressing a-SMA were found in the fibrotic interstitium of obstructed kidneys and these cells may produce interstitial ECM components such as collagen I and fibronectin. 34 The increased expression of TGF-b undoubtedly is important in the induction of EMT and stimulates progressive interstitial fibrosis during the pathogenesis of interstitial nephritis and fibrosis. 35 We demonstrated clearly that the expression of a-SMA, collagen I, and PCNA was decreased by treatment with PPAR-g agonists. Moreover, by using double immunostaining for a-SMA with PCNA, we noted an increased number of double-positive myofibroblasts present within the interstitium. These data thus suggest that PPAR-g agonists inhibit renal fibrosis in UUO.
We also examined the level of macrophage infiltration in UUO. Interstitial inflammation develops early in the course of obstructive nephropathy as a consequence of upregulation of the rennin-angiotensin system and production of proinflammatory cytokines and chemokines. This results in the interstitial infiltration by activated macrophages that have a crucial role in the renal inflammatory response during UUO. Previous in vivo studies demonstrated that PPAR-g agonists reduced interstitial macrophage infiltration in progressive renal disease in the rat and a model of murine sepsis. 17, 18, 36 On the other hand, Panzer reported that MCP-1 expression and monocyte-macrophage infiltration were enhanced during the induction phase in a model of experimental glomerulonephritis. 37 These different findings may be attributable to the different times studied after induction of glomerulonephritis. The experimental glomerulonephritis model is a short-term model of the 24 h period following induction, whereas the model used in our study investigated the period of at least 72 h after onset. The time of administration was also different from the experimental glomerulonephritis model. In fact, our study showed that pretreatment of the mouse model for 7 days before surgery was more effective than 3 days of pretreatment. As expected, pretreatment of the mice 3 days before surgery was more effective than mice who received no treatment before surgery. We demonstrated clearly that the interstitial expression of F4/80 and PCNA was decreased by treatment with PPAR-g agonists. These data suggest that PPAR-g agonists act to limit the extent of renal inflammation in UUO.
Finally, we examined the cause of renal interstitial fibrosis and inflammation in UUO. Many studies have demonstrated that obstructive nephropathy leads to activation of the intrarenal rennin-angiotensin system. The consequent increase in the level of angiotensin II has crucial direct and indirect roles in the initiation and progression of obstructive nephropathy by stimulating the production of molecules such as TGF-b1, tumor necrosis factor-a, osteopontin, vascular cell adhesion molecule-1, and nuclear factor-kB that contribute to renal fibrosis and renal cell apoptosis. 38 Of these cytokines, TGF-b1 and its receptor TGFbR-I have a particularly important role in the progression of renal injury. 39 Indeed, Miyajima et al 40 demonstrated previously that a function blocking monoclonal antibody to TGF-b reduced the extent of renal fibrosis and apoptosis in the obstructed kidneys of rats. Moon et al 35 demonstrated previously that the TGFbR-I kinase activin receptor-like kinase (ALK)5 inhibitor had protective effects on renal interstitial fibrosis following UUO in rats. In summary, these studies showed that TGF-b is a key player in renal interstitial disease. Also, in other organs, the administration of PPAR-g agonists suppresses the fibrogenic effects of hepatic stellate cells and lung fibroblasts via effects on TGF-b. 41, 42 Moreover, PPAR-g agonists can directly decrease glomerular TGF-b expression in both diabetic and nondiabetic model rats independent of its effect on glycemic control. 19, 43 In vitro studies by Hong et al demonstrated that cytoplasmic phosphorylation of Smad2/3 that act to stimulate TGF-b-dependent nuclear events was unaffected by PPAR-g agonists, whereas PPAR-g agonists were found to inhibit Smad2/3 phosphorylation either through direct interaction with TGFbR-I or with nonphosphorylated Smads. 44 In this study, we demonstrated that a PPAR-g agonist significantly reduced the expression of both TGF-b1 and TGFbR-I at 7 days after UUO. Taken together, these data suggest that PPAR-g agonists inhibit renal interstitial disease in UUO by reducing TGF-b expression with subsequent beneficial effects on fibrosis and inflammation.
Previous studies indicated that the increased renal production of TGF-b1 and TGFbR-I is mainly in the proximal tubular cells of rats with UUO. 45 Our studies showed that TGFbR-I was localized predominantly in the tubular epithelial cells and suggested that tubular epithelial cells are the primary targets of PPAR-g agonists in UUO.
In this study, we used troglitazone as an example of a synthetic PPAR-g ligand. In addition to our study, several other clinical and in vivo studies have demonstrated troglitazone has a renal protective effect. 12, 15, 21 Studies have also shown TZDs have the potential to activate a third pathway, mitogen-activated protein kinase, and specifically phosphorylated extracellular signal-regulated kinase, in addition to the PPAR-g and mitochondrial pathways in vitro. [46] [47] [48] It is therefore possible that the renal protective effect of troglitazone we observed in our study may be attributable to factors other than the PPAR-g pathway.
In conclusion, pretreatment with a PPAR-g agonist attenuated renal interstitial fibrosis and inflammation in the model of UUO through reduction of TGF-b expression. The decreased interstitial fibrosis results from less severe tubular phenotypical changes, reduced accumulation of interstitial myofibroblasts, and collagen I and downregulation of renal TGF-b1 expression. These anti-inflammatory effects were accompanied by a decrease in the level of interstitial macrophage infiltration. Therefore, the administration of exogenous TZDs may act to limit the progression of chronic fibrotic kidney disease.
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